

Generic Name: Tenofovir Alafenamide

Therapeutic Class or Brand Name: Vemlidy®

Applicable Drugs (if Therapeutic Class): N/A

GPI Code: 1235208320

Preferred: Entecavir (generic), Tenofovir Disoproxil Fumarate (generic)

Non-preferred: Vemlidy®

Date of Origin: 7/31/2018

Date Last Reviewed / Revised: 8/19/2019

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I through III are met)

- I. Patient is 18 years of age or older and ONE of the following criteria (A - D) is met:
 - A. Patient has documented diagnosis of chronic hepatitis B virus infection and has compensated liver disease
 - B. Patient is post-liver transplantation with an anti-HBc-positive graft while patient was HBsAg-negative prior to transplant (Note: anti-HBc = antibody to hepatitis B core antigen; HBsAg = hepatitis B surface antigen)
 - C. Patient is post-liver transplantation and had documented chronic hepatitis B infection prior to transplant
 - D. Patient with prior history of hepatitis B infection who is undergoing immunosuppression related to solid organ transplantation
- II. Prescriber is a Gastroenterologist, Infectious Disease Specialist, or Hepatologist.
- III. Patient cannot take entecavir or tenofovir disoproxil fumarate due to prior treatment failure, adverse effects, or contraindications

EXCLUSION CRITERIA

- N/A

OTHER CRITERIA

- Patient must have a recent documented negative test for HIV-1 infection, unless Vemlidy is being prescribed in combination with other antivirals as part of an HIV-1 co-infection treatment regimen

QUANTITY / DAYS SUPPLY RESTRICTIONS

- 30 tablets or 630mls per 30 days.

APPROVAL LENGTH

- **Authorization:** 1 year.
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

REFERENCES

1. https://www.gilead.com/~media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf?la=en .
2. <https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29800> .
3. Medi-Span®.

HISTORICAL TRACKING OF CHANGES MADE TO POLICY

Date	Notes/Changes
8/19/2019	1. Policy reviewed – no changes.
7/31/2018	1. Policy created.

DISCLAIMER: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.